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458Different Risk Factors Related to Adenovirus- or BK
Virus-Associated Hemorrhagic Cystitis following
Allogeneic Stem Cell Transplantation
Yasuo Mori,1,2 Toshihiro Miyamoto,1 Koji Kato,1 Kenjiro Kamezaki,1 Takuro Kuriyama,1
Seido Oku,1 Katsuto Takenaka,1 Hiromi Iwasaki,2 Naoki Harada,1 Motoaki Shiratsuchi,3
Yasunobu Abe,3 Koji Nagafuji,1 Takanori Teshima,2 Koichi Akashi1,2Virus-associated hemorrhagic cystitis (HC) is a major cause of morbidity and mortality following allogeneic
hematopoietic stem cell transplantation (HSCT). Although numerous studies have attempted to identify
factors that predispose patients to viral HC, its causes remain controversial. We analyzed retrospectively
the results of 266 allogeneic HSCTs to identify factors associated with HC. Of this group, 42 patients
(15.8%) were diagnosed with viral HC, because of either adenovirus (ADV; n 5 26; 9.8%) or BK virus
(BKV; n5 16; 6.0%). ADV-HCwas frequently associated with T cell purging, and was less common in patients
with acute graft-versus-host-disease (GVHD). Conversely, BKV-HC was more frequently observed in
patients with excessive immune reactions such as GVHD, preengraftment immune reaction, and hemopha-
gocytic syndrome. These observations indicate that ADV- and BKV-HC may differ significantly in their risk
factors and pathogenesis. Profound immune deficiency is more likely to be associated with ADV-HC,
whereas immune hyperactivity might play a key role in BKV-HC.
Biol Blood Marrow Transplant 18: 458-465 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Hemorrhagic cystitis, Adenovirus, BK virus, Stem cell transplantation, Immune reactionINTRODUCTION
Hemorrhagic cystitis (HC) is one of the most com-
mon complications following hematopoietic stem
cell transplantation (HSCT), which remarkably de-
creases patients’ quality of life, and potentially causes
therapy-related mortality [1-3]. Clinical manifestations
of HC vary from painless microscopic hematuria to
gross hematuria, clot formation within the urinary
tract, and obstructive renal failure [4]. Early-onset HC
that occurs during or shortly after high-dose chemo-
therapy as part of the conditioning regimen is generally1Department of Medicine and Biosystemic Science; 2Cen-
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6/j.bbmt.2011.07.025related to cyclophosphamide (CY) toxicity, whereas
late-onset HC is mainly attributed to viral infection.
BK virus (BKV) is most frequently associated with
late-onset HC [5-10], although adenovirus (ADV)-
and JC virus (JCV)-associated HC also occur: ADV
type 11 is the prominent pathogen for HC, especially
in Japan [11-17]. In general, primary ADV and BKV
infections typically occur during childhood and remain
latent in the genitourinary tract, but these viral
infections are prevalent in allo-HSCT recipients and
can cause viral-induced HC [1,2].
A number of retrospective studies have pro-
posed a variety of risk factors for HC following allo-
geneic HSCT (allo-HSCT), including busulfan
(BU)-containing myeloablative conditions, unrelated
donors, and the occurrence of graft-versus-host dis-
ease (GVHD); however, these risk factors were not ob-
served consistently. The analysis of risk factors is
likely to be complicated by many variables, including
the clinical definitions of HC, the HSCT protocols,
or the number and age of patients analyzed. We per-
formed a retrospective analysis of 42 Japanese adult
allo-HSCT recipients with either ADV-HC (n 5 26)
or BKV-HC (n 5 16), confirmed by polymerase
chain reaction (PCR) examination, to identify risk
factors for viral HC.
Table 1. Pretransplantation Characteristics of the 266 Patients
Characteristics Total
ADV-HC
(n 5 26)
BKV-HC
(n 5 16)
No-HC
(n 5 224)
P Value
ADV versus No BKV versus No
Age, median (range) 48 (16-69) 48.5 (17-69) 52 (29-63) 46.5 (16-68) .34 .21
Sex, male/female 152/114 17/9 11/5 124/100 .33 .3
Underlying disease .004 .27
MDS/AML 106 5 10 91
CML 11 1 1 9
ALL 33 1 1 31
ML 80 11 2 67
AA 14 4 0 10
Others 22 4 2 16
Disease status at transplantation .9 .011
Standard risk 123 13 1 109
High risk 143 13 15 115
Conditioning regimen .93 .58
Conventional 134 13 7 114
Reduced intensity 132 13 9 110
Stem cell source .66 .55
Related PB 69 6 6 57
Related BM 14 3 0 11
Unrelated BM 105 8 5 92
Unrelated CB 64 7 5 52
Haploidentical PB/BM 14 2 0 12
Cycles of prior therapies, median (range) 5 (0-23) 4 (0-23) 4.5 (0-12) 5 (0-19) .68 .79
Times of HSCT .14 .5
1st 190 22 10 158
$2nd 76 4 6 66
HLA matching .6 .17
Full-matched 143 13 6 124
Mismatched 123 13 10 100
GVHD prophylaxis* .61 .5
CsA-based 126 11 9 106
FK-based 139 15 7 117
In vivo T cell purging .025 .8
Yes 19 5 0 14
No 247 21 16 210
IgG-antibody for ADV (titer) .84 .26
# 4 159 15 11 133
8 13 1 0 12
16 32 3 1 28
Unknown 62 7 4 51
MDS/AML indicates myelodysplastic syndrome/acute myelogenous leukemia; CML, chronic myelogenous leukemia; ALL, acute lymphoblastic leukemia;
ML, malignant lymphoma; AA, aplastic anemia; PB, peripheral blood; BM, bone marrow; CB, cord blood; HSCT, hematopoietic stem cell transplantation;
CsA, cyclosporine; FK, tacrolimus; GVHD, graft-versus-host disease; ADV, adenovirus; BKV, BK virus.
*One case that used only mPSL (methylprednisolone) was excluded.
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Patients
The medical records of 266 patients (152 men and
114 women; median age 5 48 years), who underwent
allo-HSCT at Kyushu University Hospital between
January 2002 and June 2010, were reviewed; a subset
of these patients has been described earlier [11].
Patient characteristics are listed in Table 1. Primary
diseases included myelodysplastic syndrome (MDS)/
acute myeloid leukemia (AML; n 5 106), chronic my-
elogenous leukemia (n5 11), acute lymphoblastic leu-
kemia (ALL; n 5 33), malignant lymphoma (n 5 80),
aplastic anemia (n5 14), and others (n5 22). Patients
with any of the following conditions were classified as
standard risk: acute leukemia (AML or ALL) in remis-
sion; chronic myelogenous leukemia in chronic phase;
MDS classified as refractory anemia orrefractoryanemia with ringed sideroblasts. All others (n 5 143)
were categorized as high risk. This study was approved
by the institutional review board of Kyushu University
Hospital.
Transplantation Procedures
A total of 134 patients received conventional prepar-
ative regimens, either 12 Gy total body irradiation/CY
(n5 94) or BU/CY (n5 40). The remaining 132 cases
received purine analog-based reduced-intensity condi-
tioning consisting of either fludarabine (Flu)/CY (n 5
25), Flu/BU (n 5 69), or Flu/melphalan (n 5 38).
Low-dose total body irradiation (2-4 Gy), antithymo-
cyte globulin (ATG), and alemtuzumab were adminis-
tered in 73, 14, and 4 cases, respectively (Table 1). The
sources of stem cells included related granulocyte
colony-stimulating factor-mobilized peripheral blood
(n 5 82), related bone marrow (n 5 15), unrelated
460 Biol Blood Marrow Transplant 18:458-465, 2012Y. Mori et al.bone marrow (n 5 105), or unrelated cord blood (n 5
64). Human leukocyte antigen (HLA)-matching varied
from haploidentical (3 of 6) to identical (6 of 6). Of
266 patients, 126 and 139 received cyclosporine- or
tacrolimus-based GVHD prophylaxis, respectively; the
remaining 1 patient receivedmethylprednisolone alone.
A total of 76 patients had received at least 1 prior autol-
ogous (n 5 28) or allogeneic (n 5 48) HSCT, and the
reason of second or more transplantations was either
relapse (n 5 65) or graft failure (n 5 11) (Table 1).
Acyclovir was given as prophylaxis against herpes sim-
plex virus reactivation, 1000 mg/day orally from days
27 to 35 after HSCT.Diagnosis and Treatment of Viral HC
Urinalysis was routinely performed at least once
a week beginning with the initiation of preparative reg-
imens until discharge or when clinical signs of cystitis
appeared after that. If microscopic or macroscopic
hematuria and/or bladder irritation existed, urine was
further analyzed by rapid immunochromatography
and PCR method to detect ADV antigen [11] or
ADV, as well as BKV and JCV, viral DNA. Only pa-
tients with viruria confirmed by PCR were diagnosed
with viral HC and included in our analysis.
All patientswithviralHCwere treatedby supportive
modalities including hyperhydration, forced diuresis,
and/or blood transfusions. In addition, continuous blad-
der irrigation and/or administration of antiviral agents
were performed based on each physician’s decision. Ac-
cording to previous reports with a minor modification
[9,10], the response criteria were defined as follows:
complete response (CR), the complete resolution of
HC symptoms accompanied by eradication of ADV or
at least a 2-log reduction of BKV viral load; partial
response (PR), a significant improvement of HC
symptoms accompanied by persisting microhematuria
or continued detection of ADV or BKV in the urine
samples; and no change, no improvement or worsening
of HC.Statistical Analysis
The aim of this study was to identify factors corre-
lating with the development of viral HC. Chi-square
tests were used for univariate comparisons to examine
categoric variables, including sex, underlying diseases,
disease status, conditioning regimen, stem cell source,
HLA matching, GVHD prophylaxis, and prior
HSCT. A numerical variable (age) was compared using
the Mann-Whitney test. Odds ratios (ORs) were
calculated using a logistic regression analysis, and vari-
ables were analyzed using amultivariate stepwise logis-
tic regression model. Survival following allo-HSCT
was measured from the date of stem cell infusion until
the date of death. The survival period was calculatedusing the Kaplan-Meier method. P values\.05 were
considered statistically significant. All statistical analy-
ses were performed using SPSS 17.0 software (SPSS
Japan Inc., Tokyo, Japan).RESULTS
Incidence of Viral HC
In our series, a total of 42 of 266 allo-HSCT recip-
ients (15.8%) developed viral HC. Of these, 26 (9.8%)
were diagnosed with ADV-HC, including coinfection
with BKV (n 5 3) or JCV (n 5 1), and 16 (6.0%) with
BKV-HC alone. The immunochromatography assay
for ADV antigen was positive in 20 of 24 tested urine
samples of ADV-HC patients, although false-positive
results were obtained in 4 of 13 BKV-HC patients,
confirming the reliability of this assay for diagnosing
ADV-HC [11].
ADV-HC has predominantly been reported from
Japanese transplantation centers [11-17], whereas
BKV-HC is frequently seen worldwide [5-10].
Because the role of BKV in HC pathogenesis remains
unclear, because it is commonly found in the urine of
unaffected patients, we analyzed ADV-HC and
BKV-HC separately and compared it to patients with-
out HC (n 5 224).Pretransplantation Characteristics of Patients
with ADV-HC and BKV-HC
Six of 128 (4.7%) patients who underwent HSCT
for acute leukemia (MDS/AML and ALL) developed
ADV-HC, which was significantly less frequent than
in the 20 of 122 (16.4%) patients suffering from other
disorders (P 5 .004). A high incidence of ADV-HC
was found in patients who received T cell purging us-
ing ATG or alemtuzumab (26.3%; 5 of 19) compared
with those who did not (9.1%; 21 of 231; P 5 .025).
Some studies have reported a close association be-
tween positive results of anti-ADV antibody and the
development of ADV-HC [12,16], whereas another
group [14] and our study could not detect such a
relationship between them (Table 1). In contrast,
BKV-HC was closely related to the status of underly-
ing diseases at HSCT: high-risk patients developed
BKV-HC more frequently than standard-risk patients
(11.5%, n 5 130 versus 0.9%, n 5 110; P 5 .011).
There was no association among viral HC with sex,
stem cell source, or HLA matching. Moreover, the in-
cidence of viral-HC was not affected by the usage of
BU (BU-containing, 12.8%, n 5 109 versus non-BU,
17.8%, n5 157; P5 0.27), usage of CY (CY-contain-
ing, 16.4%, n 5 159 versus non-CY, 15.0%, n 5 107;
P 5 0.76), or prior history of treatment (number of
cycles of pretransplantation therapy) (Table 1).
Table 2. Clinical and Laboratory Manifestations of Viral-Associated HC
Case Diagnosis Graft Conditioning
Preengraftment
Allo-reaction
Maximum
Grade
of GVHD
Immunosuppressive
Agents at HC Onset
Onset
(Day) Hematuria
Bladder
Irritation ADV-IC
Viruria
(PCR)
Antiviral
Agents Response
CMV
Reactivation
VZV
Reactivation Outcome
1 LPL UBM Conv (2) (2) FK 2 macro No (+) ADV CDV CR (2) (2) survive
2 AA RBM RIC (ATG) NA NA FK 4 macro Yes (+) ADV CDV CR NA (2) dead by
infection
3 AA RBM RIC (Campath) (2) (2) CsA 7 OB No (+) ADV CDV CR antigenemia (+) survive
4 ATL UCB Conv NA NA CsA 7 macro Yes (2) ADV CDV + FCV PR (viruria+) NA (2) ATL relapse
5 ATL UCB RIC HPS (2) FK 11 macro No (+) ADV + BKV CDV PR (viruria+) (2) (2) dead by
bleeding
6 HPS UCB RIC (ATG) (2) (2) FK/PSL 13 macro Yes (+) ADV + BKV CDV PR (viruria+) antigenemia (2) survive
7 ATL RPB Conv PIR acute(IV) CsA/mPSL 19 OB Yes (+) ADV CDV PR (OB+) antigenemia (2) dead by
infection
8 NK leukemia UCB Conv (2) (2) CsA/PSL 22 macro Yes (+) ADV CDV + ribavirin NC antigenemia (2) survive
9 AA haplo-BM Conv (2) acute(II) FK/PSL 25 macro No (+) ADV CDV CR antigenemia (2) survive
10 PTCL-u UCB RIC (2) (2) FK 29 OB Yes (+) ADV GCV CR gastritis (+) survive
11 AA UBM RIC (ATG) PIR (2) CsA 30 macro Yes (+) ADV CDV PR (OB+) antigenemia (2) dead by
bleeding
12 AML UBM Conv HPS acute(II) FK/PSL 31 macro No (+) ADV None CR antigenemia (+) dead by PD
13 NK lymphoma RPB RIC PIR acute(IV) FK/mPSL 47 macro Yes (+) ADV CDV CR colitis (2) dead by
TMA
14 MM RPB RIC (2) chronic(extensive) CsA/PSL 79 OB Yes (+) ADV CDV CR antigenemia (2) survive
15 ATL haplo-PB RIC (ATG) (2) (2) FK/PSL 120 macro Yes (+) ADV CDV CR antigenemia (2) survive
16 AML UBM Conv (2) (2) FK 144 macro Yes (2) ADV CDV CR antigenemia (2) survive
17 AITL UCB RIC PIR acute(III) CsA/PSL/MMF/
basiliximab
149 macro No NA ADV CDV CR antigenemia (2) dead by
infection
18 MDS/AML RPB RIC PIR acute(II) CsA/PSL 183 macro Yes (+) ADV CDV PR (OB+) antigenemia (2) dead by PD
19 MF RPB Conv (2) chronic (extensive) CsA/PSL 184 macro Yes (+) ADV CDV CR (2) (+) survive
20 HCL RPB Conv PIR acute(II),
chronic(limited)
CsA/PSL 265 OB Yes (+) ADV CDV CR (2) (2) survive
21 AML RBM Conv (2) acute(I), chronic
(extensive)
CsA/PSL 266 macro Yes NA ADV None CR (2) (2) survive
22 CML RBM Conv (2) chronic(extensive) PSL 281 macro Yes (+) ADV CDV CR antigenemia (2) survive
23 MF UBM RIC (2) (2) FK/PSL 368 macro Yes (+) ADV CDV CR antigenemia (2) survive
24 AML UBM Conv (2) (2) (2) 455 macro Yes (2) ADV + JCV None PR (viruria+) gastritis/colitis (2) dead by PD
25 ALL UCB RIC (2) (2) (2) 484 macro No (+) ADV CDV CR (2) (2) survive
26 DLBCL UBM Conv PIR chronic(limited) FK 875 macro Yes (2) ADV + BKV CDV CR antigenemia (+) survive
27 AML UCB RIC HPS (2) CsA 6 OB Yes (+) BKV None CR antigenemia (2) dead by PD
28 ALL UBM Conv PIR acute(II) FK 7 OB Yes (2) BKV None PR (OB+) antigenemia (2) dead by PD
29 Gastric Ca RPB RIC HPS NA CsA/PSL 11 macro No (2) BKV None NC NA (2) dead by
infection
30 DLBCL UCB RIC PIR acute(III) CsA/PSL 29 macro Yes NA BKV None NC (2) (2) dead by PD
31 MDS/AML UBM Conv (2) acute(III) FK/mPSL/MMF/
basiliximab
40 macro No NA BKV None NC antigenemia (2) dead by
GVHD
32 ATL UCB RIC PIR acute(II) CsA 42 macro Yes (2) BKV None CR antigenemia (2) dead by PD
33 MDS/AML RPB Conv PIR acute(II) CsA/mPSL 44 OB Yes (2) BKV None CR antigenemia (+) dead by PD
34 MDS/AML RPB RIC (2) acute(II) CsA/mPSL 49 macro Yes (+) BKV None CR antigenemia (2) dead by PD
35 MDS/AML UBM RIC PIR acute(II) FK/mPSL 50 OB Yes (2) BKV None CR antigenemia (2) dead by PD
B
io
l
B
lo
o
d
M
a
rro
w
T
ra
n
sp
la
n
t
1
8
:4
5
8
-4
6
5
,
2
0
1
2
4
6
1
V
ira
l
H
e
m
o
rrh
a
gic
C
ystitis
fo
llo
w
in
g
a
llo
-H
S
C
T
3
6
A
M
L
U
B
M
C
o
nv
P
IR
ac
u
te
(I
V
)
FK
/P
SL
/M
M
F/
et
an
er
ce
p
t
5
2
m
ac
ro
N
o
(+
)
B
K
V
C
D
V
P
R
(v
ir
u
ri
a+
)
(2
)
(2
)
d
ea
d
b
y
G
V
H
D
3
7
A
M
L
U
C
B
R
IC
P
IR
ac
u
te
(I
II
)
C
sA
/P
SL
6
1
m
ac
ro
Ye
s
(2
)
B
K
V
C
D
V
P
R
(O
B
+
)
an
ti
ge
n
em
ia
(2
)
A
M
L
re
la
p
se
3
8
A
M
L
U
C
B
C
o
nv
P
IR
(2
)
C
sA
6
6
m
ac
ro
Ye
s
(2
)
B
K
V
N
o
n
e
P
R
(O
B
+
)
an
ti
ge
n
em
ia
(2
)
d
ea
d
b
y
in
fe
ct
io
n
3
9
M
D
S/
A
M
L
R
P
B
R
IC
P
IR
ac
u
te
(I
I)
C
sA
/P
SL
8
6
m
ac
ro
N
o
(2
)
B
K
V
C
D
V
P
R
(v
ir
u
ri
a+
)
an
ti
ge
n
em
ia
(2
)
su
rv
iv
e
4
0
A
M
L
R
P
B
C
o
nv
H
P
S
ch
ro
n
ic
(l
im
it
ed
)
C
sA
/P
SL
1
2
2
m
ac
ro
N
o
N
A
B
K
V
C
D
V
+
A
ra
-A
P
R
(v
ir
u
ri
a+
)
an
ti
ge
n
em
ia
(2
)
d
ea
d
b
y
P
D
4
1
T
hy
m
ic
C
a
R
P
B
R
IC
(2
)
ac
u
te
(I
I)
,
ch
ro
n
ic
(e
x
te
n
si
ve
)
C
sA
/P
SL
1
3
4
m
ac
ro
N
o
(2
)
B
K
V
N
o
n
e
N
C
(2
)
(2
)
d
ea
d
b
y
P
D
4
2
C
M
L
U
B
M
C
o
nv
P
IR
ch
ro
n
ic
(e
x
te
n
si
ve
)
FK
/P
SL
4
4
3
m
ac
ro
N
o
(+
)
B
K
V
N
o
n
e
N
C
an
ti
ge
n
em
ia
(2
)
d
ea
d
b
y
re
na
l
fa
ilu
re
LP
L
in
d
ic
at
es
ly
m
p
ho
p
la
sm
ac
yt
ic
ly
m
p
ho
m
a;
A
A
,a
p
la
st
ic
an
em
ia
;A
T
L,
ad
ul
t
T
ce
ll
ly
m
p
ho
m
a;
H
P
S,
h
em
o
p
h
ag
o
cy
ti
c
sy
n
d
ro
m
e;
P
T
C
L-
u
,p
er
ip
h
er
al
T
ce
ll
ly
m
p
ho
m
a
u
n
cl
as
si
fi
ed
;A
M
L,
ac
u
te
m
ye
lo
ge
n
o
u
s
le
u
ke
m
ia
;
M
M
,
m
u
lt
ip
le
m
ye
lo
m
a;
A
IT
L,
an
gi
o
im
m
u
n
o
b
la
st
ic
T
ce
ll
ly
m
p
ho
m
a;
M
D
S,
m
ye
lo
d
ys
p
la
st
ic
sy
n
d
ro
m
e;
M
F,
m
ye
lo
fib
ro
si
s;
H
C
L,
h
ai
ry
ce
ll
le
u
ke
m
ia
;
C
M
L,
ch
ro
n
ic
m
ye
lo
ge
n
o
u
s
le
u
ke
m
ia
;
A
LL
,
ac
u
te
ly
m
p
ho
b
la
st
ic
le
u
ke
m
ia
;
D
LB
C
L,
d
iff
us
e
la
rg
e
B
ce
ll
ly
m
p
ho
m
a;
U
B
M
,
u
n
re
la
te
d
b
o
n
e
m
ar
ro
w
;
R
B
M
,
re
la
te
d
b
o
ne
m
ar
ro
w
;
U
C
B
,
u
n
re
la
te
d
co
rd
b
lo
o
d
;
R
P
B
,
re
la
te
d
p
er
ip
h
er
al
b
lo
o
d
;
C
o
nv
,
co
nv
en
ti
o
na
l
co
n
d
it
io
n
in
g;
R
IC
,
re
d
uc
ed
-i
n
te
n
si
ty
co
n
d
it
io
n
in
g;
A
T
G
,a
n
ti
th
ym
o
cy
te
gl
o
b
u
lin
;N
A
,n
o
t
as
se
ss
ed
;P
IR
,p
re
en
gr
af
tm
en
t
im
m
u
n
e
re
ac
ti
o
n
;F
K
,t
ac
ro
lim
u
s;
C
sA
,c
yc
lo
sp
o
ri
n
A
;P
SL
,p
re
d
n
is
o
lo
n
e;
m
P
SL
,m
et
hy
lp
re
d
n
is
o
lo
n
e;
M
M
F,
m
y-
co
p
h
en
o
la
te
m
o
fe
ti
l;
O
B
,o
cc
u
lt
b
lo
o
d
;C
D
V,
ci
d
o
fo
vi
r;
FC
V,
fo
sc
ar
n
et
;G
C
V,
ga
n
cy
cl
o
vi
r;
C
R
,c
o
m
p
le
te
re
m
is
si
o
n
;P
R
,p
ar
ti
al
re
m
is
si
o
n
;N
C
,n
o
ch
an
ge
;V
Z
V,
va
ri
ce
lla
zo
st
er
vi
ru
s;
P
D
,p
ro
gr
es
si
ve
d
is
ea
se
;T
M
A
,
th
ro
m
bo
ti
c
m
ic
ro
an
gi
it
is
;
G
V
H
D
,
gr
af
t-
ve
rs
u
s-
h
o
st
d
is
ea
se
.
462 Biol Blood Marrow Transplant 18:458-465, 2012Y. Mori et al.Clinical Findings of ADV-HC and BKV-HC
The clinical features of patients developing viral
HC are shown in Table 2. The median onset of clinical
symptoms was 49.5 days (range: 2-875 days), consistent
with previous reports [13-15]. Most of the patients with
ADV-HC (53.8%) and BKV-HC (75%) presented
their symptoms more than 1 month after transplanta-
tion, indicating that viral HC was caused by the reacti-
vation of latent infection rather than acute infection
during the transplantation course. The frequency of
macrohematuria or bladder irritation was similar
between patients with ADV-HC and those with BKV-
HC; however, the symptoms were more severe in
ADV-HC.
At the onset of viral HC, almost all the patients
were receiving immunosuppressive agents as either
prophylaxis or treatment of GVHD or hemophago-
cytic syndrome (HPS). Interestingly, the incidence of
allogeneic immune reactions was significantly differ-
ent between patients with ADV-HC and BKV-HC.
Acute GVHD (aGVHD) (maximum; grade II to IV)
throughout the clinical course was marginally less fre-
quent in ADV-HC patients than in patients without
viral HC (P 5 .054; Table 3), possibly because of T
cell purging. In contrast, patients with BKV-HC
were more likely to have developed either noninfec-
tious fever before engraftments known as a preengraft-
ment immune reaction (PIR) [18] or HPS (80%) or
postengraftment aGVHD (grade II-IV; 73.3%) than
patients without viral HC (43.8%, P 5 .013 and
50.5%, P 5 .099, respectively; Table 3).
Finally, we found a significant or marginal increase
of proven cytomegalovirus diseases (e.g. gastritis, coli-
tis) or varicella zoster virus reactivation in ADV-HC
patients compared with non-HC individuals (12.5%
versus 3.6%, P5 .05, and 20.8% versus 12.9%, P5 .29,
respectively).Treatment and Outcome of Viral HC
In addition to supportive treatments, 8 of 46 pa-
tients withHC required continuous bladder irrigation.
Twenty-two of 26 patients with ADV-HC and 4 of 16
patients with BKV-HC were treated with low-dose
cidofovir (CDV; 1 mg/kg/day, 3 times a week), as pre-
viously reported [11]. In addition to CDV treatment,
foscarnet was subsequently administered for 1 patient,
ribavirin for 1, and Ara-A for the other because of their
inadequate responses. Clinical features were relieved
in all except 1 ADV-HC patient; 18 patients obtained
CR, 7 obtained PR with persistent viruria (n 5 4) or
microhematuria (n 5 3) without bladder irritation,
and in the remaining case, autologous stem cell rescue
for the primary graft failure improved his symptoms
(case 8). Of the 16 patients with BKV-HC, symptoms
persisted in 6 patients, although 5 of them did not re-
ceive antiviral agents because of either relapse of their
Table 3. Posttransplantation Characteristics of the 233 Engrafted Recipients
Characteristics Total ADV-HC (n 5 24) BKV-HC (n 5 15) No-HC (n 5 194)
P Value
ADV versus No BKV versus No
PIR and/or HPS .56 .013
Yes 106 9 12 85
No 127 15 3 109
aGVHD* .054 .099
No 89 16 4 69
Grade I 28 1 0 27
Grade II 79 4 7 68
Grade III 25 1 3 21
Grade IV 12 2 1 9
CMV reactivation .69 .47
Yes (antigenemia/diseases) 158/10 15/3 12/0 131/7
No 65 6 3 56
VZV reactivation .29 .49
Yes 31 5 1 25
No 202 19 14 169
PIR indicates preengraftment immune reaction; HPS, hemophagocytic syndrome; aGVHD, acute graft-versus-host disease; CMV, cytomegalovirus; VZV,
varicella zoster virus.
*Maximum grade throughout the observation period.
Statistically significant differences were indicated by italics.
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ficient organ function (Table 2).
Nine of 26 patients with ADV-HC died because of
infection (n 5 4), disease progression (n 5 3),
and bleeding (n 5 2). Of the surviving patients, 1 re-
lapsed and 16 remained disease-free. In contrast, 14
of 16 patients with BKV-HC died because of disease
progression (n 5 9), other infection (n 5 2), GVHD
(n5 2), or renal failure (n5 1), and 1 patient relapsed,
leaving a single disease-free survivor from the patients
with this complication. In our study, the 1-year overall
survival after HSCT was only 16.1% 6 10.2% for pa-
tients with BKV-HC, significantly lower than that of
patients without HC (52.5% 6 3.4%) or with ADV-
HC (63.7% 6 10.4%).Risk Factors for ADV-HC and BKV-HC
Univariate analysis using logistic regression identi-
fied strong associations between ADV-HC and (1)
the underlying disease (acute leukemia versus others;
P 5 .004), (2) T cell purging (P 5 .025), and (3) less
occurrence of severe aGVHD (grade II-IV versus
grade 0-I; P 5 .054). Multivariate logistic regression
analysis confirmed that all 3 factors had significantTable 4. Results of Multivariate Logistic Regression Analysis
Characteristics
ADV-HC
Underlying disease Others versus acute leu
In vivo T cell purging Yes versus no
aGVHD grade II to IV versus 0 to
BKV-HC
Disease status at transplantation High risk versus standar
PIR and/or HPS Yes versus no
Odds ratio were calculated by the backward or the forward stepwise selectio
Statistically significant differences were indicated by italics.or marginal association with developing ADV-HC;
ORs were 4.488 (95% confidence interval (CI) 5
1.625-12.40; P 5 .004), 4.176 (95% CI 5 0.942-
18.50; P 5 .06), and 0.390 (95% CI 5 0.148-1.025;
P 5 .054), respectively (Table 4).
Similar analysis of BKV-HC patients identified a
significant relationship with disease status at HSCT
(high risk versus standard risk; P 5 .011), PIR and/or
HPS (P 5 .013), and marginal to aGVHD (grade
II-IV versus grade 0-I; P5 .099). Multivariate analysis
showed that high-risk disease status (OR5 14.34; 95%
CI 5 1.81-113.4; P 5 .012) and presence of PIR and/
or HPS (OR5 4.13; 95% CI5 1.06-16.14; P5 .041)
were the risk factors for BKV-HC (Table 4).DISCUSSION
BKV is frequently isolated from asymptomatic pa-
tients before or following HSCT [5-8], and even from
healthy individuals [19-21], indicating that the
presence of BKV in urine samples is not always
associated with HC. In contrast, ADV is almost
exclusively detected in patients with HC, indicating
a likely causative role [11-17,22]. BKV is moreOdds Ratio (95% CI) P Value
kemia 4.488 (1.625-12.40) .004
4.176 (0.942-18.50) .06
I 0.390 (0.148-1.025) .054
d risk 14.34 (1.812-113.4) .012
4.132 (1.058-16.14) .041
n methods.
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posttransplantation patients compared with ADV,
increasing from 7% to 47% for BKV and by 4% for
ADV [6]. Despite a high BKV reactivation rate, HC
occurs in only a fraction of patients with sustained
BK viruria, whereas the majority of HSCT recipients
with ADV viruria progress to HC [6,14,23]. In our
study, we retrospectively analyzed 266 patients to
identify the typical clinical features of Japanese adult
allogeneic HSCT recipients who develop viral HC.
The cumulative incidence of viral HC was 15.8%
overall in our study group, 9.8% because of ADV
and 6.0% because of BKV. We found that the factors
associated with ADV- or BKV-HC were significantly
different.
In the present study, approximately one-half of the
ADV-HC cases were early onset (\1 month post-
HSCT) and were closely associated with the underly-
ing diseases including lymphoid malignancies and
usage of ATG or alemtuzumab as a part of condition-
ing for AA patients, consistent with previous reports
[22,24-26]. In contrast, late-onset ADV-HC (.1
month post-HSCT) was associated with chronic
GVHD (6 of 14 patients) and the administration of
prolonged immunosuppressants (12 of 14 patients;
Table 2). In addition, 15 of 24 patients with
ADV-HC were positive for the cytomegalovirus anti-
gen test throughout HSCT, possibly indicating a gen-
eral impairment of immune protection against viral
reactivation. This suggests that profound immune
suppression, such as T cell depletion or persistent
GVHD and the resultant prolonged administration
of immunosuppressants, may be a critical factor in
the etiology of ADV-HC.
Only a subset of HSCT recipients with BK viruria
progress to clinical BKV-HC, suggesting that other
factors may be involved in this complication. Previous
reports have shown that BKV-HC is extremely rare in
autologous HSCT recipients [14,27,28], although
their intensity of myeloablative preparative regimens,
as well as the level and incidence of BK viruria, were
similar among patients with autologous and
allogeneic HSCT [27]. Here we have identified a sig-
nificant association between occurrence of BKV-HC
and aGVHD or non-T cell purging, consistent with
previous reports from others [6,7,9,22,29]. Ten of
16 (62.5%) cases with BKV-HCdeveloped their symp-
toms between engraftment and 100 days post-HSCT,
in which aGVHD were frequently occurred, suggest-
ing that immune reactions mediated by donor T cells
may be an important contributing factor for develop-
ing BKV-HC. In addition, PIR and/or HPS, which
are also indicative of excessive allogeneic immune re-
actions, were more frequently observed in patients
with BKV-HC (80%, 12 of 15 patients) than among
those without viral HC (43%, 85 of 194 patients).
The lower frequency of severe aGVHD amongJapanese HSCT recipients than in Western countries
[30,31] may, in part, account for the lower incidence
of BKV-HC in Japan.
Our findings indicate that ADV- and BKV-HC
may develop because of different mechanisms in allo-
HSCT recipients. Although under normal circum-
stances, BKV and ADV remain latent in the urinary
tracts following primary infection, analysis of urine
samples using PCR indicates that BKV is able to rep-
licate in healthy adults [19-21], although it does not
typically lead to HC. BKV-HC was frequently found
in patients with excessive allogeneic immune reactions
such as GVHD, PIR, and HPS. Because BKV is
usually not sufficient to causeHC, BKVmight cooper-
ate with excessive immune reactions to cause HC,
although it remains unclear whether this immune at-
tack can target the uroepithelium or not. In contrast,
ADV is usually undetectable in the urine of healthy
adults, indicating that ADV does not replicate under
the normal immune status [32]. In the allo-HSCT re-
cipients, ADV-HC was associated with T cell purging
and the underlying disease. It is conceivable that severe
immune suppression allows ADV replication to occur
in the urinary tract, leading to local inflammation and
subsequent development of HC. Because BKV viruria
may be asymptomatic, it is likely that ADV is more
virulent than BKV for developing HC.
The influence of HC on the outcome of HSCT re-
mains controversial. In our study, 22 of 26 patients de-
veloping ADV-HC were promptly initiated low-dose
CDV, as previously reported [11], resulting in CR in
15 patients and PR in 6 others, and the 1-year overall
survival in patients with ADV-HCwas similar to those
without ADV-HC (63.7% versus 52.5%). In contrast,
patients with BKV-HC had a very low probability of
survival (\20%), although others have reported that
the clinical course of BKV-HC was less severe than
ADV-HC [6]. In these patients, the main cause of
death was not the BKV-HC but the progression of
the underlying diseases; 15 of 16 cases with BKV-
HC underwent allo-HSCT against the uncontrolled
diseases. Irrelevant immune reactions and the resultant
administration of immunosuppressants might contrib-
ute to the reduction of the graft-versus-leukemia
effect.
In conclusion, we have identified different
related factors in HSCT recipients to develop either
ADV-HC or BKV-HC, although there are the limita-
tions to a retrospective, single-center analysis. Severe
immunosuppression might play a pivotal role for
ADV reactivation and subsequent development of
ADV-HC, whereas an excessive immune reaction
might be critical for the development of BKV-HC.
Earlier diagnosis and intervention for ADV-HC with
low-dose CDV therapy may provide a survival benefit.
It will be interesting to see if these associations are
found in other adult populations.
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